durvalumab

News

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.